Whistleblower pursues Web imposter

Share this article:
In November, FDA drug safety whistleblower David J. Graham and his lawyer were in pursuit of whoever posted an anti-FDA article under his name on a Canadian Web site.

In the article on the Montreal-based Centre for Research on Globalization site, Graham purportedly wrote that it is “inevitable that drug company executives and FDA senior officials will do prison time for their crimes against humanity.” After likening drug reviewers to Nazis, the article concluded: “American medicine is now the shame of the world, and the conduct of senior officials at the FDA is nothing less than criminal. There is now no greater threat to the health and safety of the American people than the US Food and Drug Administration.”

Graham protested through his lawyer, and the offending article was taken down. In addition, its actual author, Mike Adams, an alternative-health, anti-industry writer for a related site, Newstarget.com, apologized. The Web site explained an auditor mistakenly attributed it to Graham.
Graham and his lawyer said they were satisfied by the corrective actions.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...